Patents by Inventor Christopher Meades

Christopher Meades has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7902361
    Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein R1 and R5 are each independently H, C(ORj?) or a hydrocarbyl group optionally substituted by one or more R6 groups; R2, R3, and R4 are each independently H, alkyl or alkenyl, each of which may be optionally substituted with one or more R7 groups; R6 and R7 are each independently halogen, NO2, CN, (CH2)mORa, O(CH2)nORb, (CH2)pNRcRd, CF3, COORe, CONRfRg, CORh, SO3H, SO2Ri, SO2NRjRk, (CH2)qNRa?CORg?, Rf?, (CH2)rNRb?SO2Rh?, SO2NRd?Ri?, SO2NRe?(CH2)sORc?, heterocycloalkyl or heteroaryl, wherein said heterocycloalkyl and heteroaryl may be optionally substituted by one or more substituents selected from aralkyl, sulfonyl, Rm and CORn; Rg?, Rh?, Ri? and Rj? are each independently selected from alkyl, aryl, aralkyl and heteroaryl, each of which may be optionally substituted with one or more substituents selected from halogen, OH, NO2, NH2 CF3 and COOH; m, p, q and r are each independently 0, 1, 2 or 3; n
    Type: Grant
    Filed: April 21, 2006
    Date of Patent: March 8, 2011
    Assignee: Cyclacel Limited
    Inventors: Shudong Wang, Gavin Wood, Kenneth Duncan, Christopher Meades, Darren Gibson, Janice McLachlan, Alex Perry, David Blake, Daniella I. Zheleva, Peter Martin Fischer
  • Patent number: 7897605
    Abstract: The present invention relates to substituted pyrimidines of formula I, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders and/or viral disorders.
    Type: Grant
    Filed: July 29, 2008
    Date of Patent: March 1, 2011
    Assignee: Cyclacel Limited
    Inventors: Shudong Wang, Christopher Meades, Gavin Wood, Janice O'Boyle, Campbell McInnes, Peter Martin Fischer
  • Publication number: 20090318446
    Abstract: The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof. The present invention seeks to provide further substituted heteroaryl-substituted pyrimidine derivatives. More specifically, the invention relates to compounds that have broad therapeutic applications in the treatment of a number of different diseases and/or that are capable of inhibiting one or more protein kinases.
    Type: Application
    Filed: January 11, 2006
    Publication date: December 24, 2009
    Applicant: Cyclacel Limited
    Inventors: Peter Martin Fischer, Shudong Wang, Christopher Meades, Matin J.I. Andrews, Darren Gibson, Kenneth Duncan
  • Publication number: 20090215805
    Abstract: The present invention relates to compounds of formula (I) or formula (II), or pharmaceutically acceptable salts thereof. Further aspects relate to pharmaceutical compositions comprising compounds according to the invention, and the use of said compounds in the preparation of a medicament for treating a variety of disorders, including proliferative disorders, viral disorders, stroke, etc.
    Type: Application
    Filed: October 9, 2006
    Publication date: August 27, 2009
    Applicant: Cyclacel Limited
    Inventors: Gavin Wood, Christopher Meades, Peter Martin Fischer, Shudong Wang, Kenneth Duncan, Daniella I. Zheleva, Campbell Mcinnes, Mark Thomas
  • Publication number: 20090137572
    Abstract: The present invention relates to selected substituted pyrimidines their preparation, pharmaceutical compositions containing them and their use as inhibitors of one or more protein kinases, and hence their use in the treatment of proliferative disorders, viral disorders and/or other disorders.
    Type: Application
    Filed: May 26, 2005
    Publication date: May 28, 2009
    Inventors: Shudong Wang, Gavin Wood, Kenneth Duncan, Christopher Meades, Darren Gibson, Janice McLachlan, Peter Martin Fischer
  • Publication number: 20080287439
    Abstract: The present invention relates to substituted pyrimidines of formula I, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders and/or viral disorders.
    Type: Application
    Filed: July 29, 2008
    Publication date: November 20, 2008
    Applicant: Cyclacel Limited
    Inventors: Shudong Wang, Christopher Meades, Gavin Wood, Janice O'Boyle, Campbell McInnes, Peter Martin Fischer
  • Patent number: 7432260
    Abstract: The present invention relates to substituted pyrimidines of formula I, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders and/or viral disorders.
    Type: Grant
    Filed: November 17, 2004
    Date of Patent: October 7, 2008
    Assignee: Cyclacel Limted
    Inventors: Shudong Wang, Christopher Meades, Gavin Wood, Janice O'Boyle, Campbell McInnes, Peter Martin Fischer
  • Patent number: 7427627
    Abstract: The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: September 23, 2008
    Assignee: Cyclacel Limited
    Inventors: Shudong Wang, Christopher Meades, Andrew Osnowski, Gavin Wood, Peter Martin Fischer
  • Patent number: 7388015
    Abstract: The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: June 17, 2008
    Assignee: Cyclacel Limited
    Inventors: Shudong Wang, Christopher Meades, Andrew Osnowski, Gavin Wood, Peter Martin Fischer
  • Publication number: 20080063608
    Abstract: A pharmaceutical composition comprising: (a) an anticholinergic of formula 1 wherein X? is an anion with a single negative charge; (b) a corticosteroid; and (c) a betamimetic, wherein each component (a), (b), and (c) are optionally in the form of the solvates or hydrates thereof, processes for preparing them, and their use in the treatment of respiratory diseases.
    Type: Application
    Filed: June 7, 2007
    Publication date: March 13, 2008
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Michael Pieper, Christopher Meade, Michel Pairet
  • Publication number: 20070256412
    Abstract: The present invention relates to a turbocharger assembly lock comprising a retaining ring partially disposed in a circumferential groove of a first turbocharger stage component and partially in a circumferential groove of a second turbocharger stage component so that the turbocharger stages are securely attached to each other.
    Type: Application
    Filed: May 8, 2006
    Publication date: November 8, 2007
    Inventors: Steven Martin, Christopher Meade, Andrew McGraw
  • Publication number: 20070196206
    Abstract: The present invention relates to a turbocharger compressor diffuser loading plate that is in contact with a vaned diffuser and that is in communication with the compressor volute. The diffuser loading plate is pressure loaded so that it moves axially in response to pressure thereby maintaining an effective seal of the open side of the vaned diffuser. The present invention minimizes a loss in compressor performance caused by movement of the compressor housing.
    Type: Application
    Filed: February 17, 2006
    Publication date: August 23, 2007
    Inventors: Steven Martin, Christopher Meade, Voytek Kanigowski
  • Publication number: 20070101715
    Abstract: A turbocharger includes a compressor housing and a turbine housing wherein at least one of the compressor housing and the turbine housing includes an anti-ballistic material such as, for example, aramid fibers, S glass fibers and/or carbon fibers. A turbocharger system optionally includes a temperature controller that controls temperature in instances where operational temperatures may be detrimental to the performance characteristics of anti-ballistic material. Various other exemplary devices, methods, systems, etc., are also disclosed.
    Type: Application
    Filed: November 7, 2005
    Publication date: May 10, 2007
    Inventors: Steven Martin, Christopher Meade, Syed Shahed
  • Publication number: 20070021452
    Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein R1 and R5 are each independently H, C(ORj?) or a hydrocarbyl group optionally substituted by one or more R6 groups; R2, R3, and R4 are each independently H, alkyl or alkenyl, each of which may be optionally substituted with one or more R7 groups; R6 and R7 are each independently halogen, NO2, CN, (CH2)mORa, O(CH2)nORb, (CH2)pNRcRd, CF3, COORe, CONRfRg, CORh, SO3H, SO2Ri, SO2NRjRk, (CH2)qNRa?CORg?, Rf?, (CH2)rNRb?SO2Rh?, SO2NRd?Ri?, SO2NRe?(CH2)sORc?, heterocycloalkyl or heteroaryl, wherein said heterocycloalkyl and heteroaryl may be optionally substituted by one or more substituents selected from aralkyl, sulfonyl, Rm and CORn; Rg?, Rh?, Ri? and Rj? are each independently selected from alkyl, aryl, aralkyl and heteroaryl, each of which may be optionally substituted with one or more substituents selected from halogen, OH, NO2, NH2 CF3 and COOH; m, p, q and r are each independently 0, 1, 2 or 3
    Type: Application
    Filed: April 21, 2006
    Publication date: January 25, 2007
    Applicant: Cyclacel Limited
    Inventors: Shudong Wang, Gavin Wood, Kenneth Duncan, Christopher Meades, Darren Gibson, Janice McLachlan, Alex Perry, David Blake, Daniella Zheleva, Peter Fischer
  • Publication number: 20070021333
    Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics and soluble TNF receptor fusion proteins, processes for preparing them and their use in the treatment of respiratory diseases.
    Type: Application
    Filed: February 7, 2004
    Publication date: January 25, 2007
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Christopher Meade, Michael Pieper, Michel Pairet
  • Publication number: 20070015749
    Abstract: The invention relates to the use of pteridines for the treatment of inflammatory and obstructive respiratory complaints, preferably asthma or COPD, as well as pharmaceutical compositions containing these compounds.
    Type: Application
    Filed: September 19, 2006
    Publication date: January 18, 2007
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Peter NICKOLAUS, Christopher Meade, Domnic Martyres, Juergen Mack, Birgit Jung, Horst Dollinger, Georg Dahmann
  • Publication number: 20060286040
    Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics of the formula 1; wherein X?, R1 ? and Ar are defined as in claim 1, and a heterocyclic compound of the formula 2. Furthermore, the invention relates to processes for preparing them and their use in the treatment of respiratory complaints.
    Type: Application
    Filed: August 5, 2004
    Publication date: December 21, 2006
    Applicant: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Christopher Meade, Michel Pairet, Michael Pieper, Yuzuru Abe, Ichiro Miki
  • Publication number: 20060276441
    Abstract: A pharmaceutical composition comprising: (a) a salt of formula 1 wherein: X? is an anion with a single negative charge; and (b) a steroid 2, processes for preparing such pharmaceutical composition, and their use in the treatment of respiratory complaints.
    Type: Application
    Filed: April 20, 2006
    Publication date: December 7, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rolf Banholzer, Helmut Meissner, Gerd Morschhaeuser, Michael Pieper, Gerald Pohl, Richard Reichl, Georg Speck, Christopher Meade, Michel Pairet
  • Publication number: 20060251656
    Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergies and anti-TNF antibodies, processes for preparing them and their use in the treatment of respiratory diseases.
    Type: Application
    Filed: February 7, 2004
    Publication date: November 9, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Christopher Meade, Michael Pieper, Michel Pairet
  • Publication number: 20060241297
    Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein: (A) “a” is a single bond and “b” is a double bond; R1 and R2 are each independently as defined below; R10 is absent; or (B) “a” is a double bond and “b” is a single bond; R1 is oxygen; R2 is as defined below; and R10 is H or alkyl; X is S, O, NH, or NR7; Y is N or CR8; one of Z1, Z2, and Z3 is N or N+Ra and the remainder are each independently CR7; R1, R2, R5 and R6 are each independently R7; R3 and R4 are each independently R8; each R7 is independently H, halogen, NRbRc, ORd or a hydrocarbyl group optionally substituted by one or more R9 groups; each R8 is independently H or (CH2)nR9, where n is 0 or 1; each R9 is independently selected from H, halogen, NO2, CN, Re, NHCORf, CF3, CORg, NRhRi, CONRjRk, SO2NRlRm, SO2Rn, ORp, OCH2CH2ORq, morpholine, piperidine and piperazine; and Ra-q are each independently H or alkyl, wherein said alkyl group is optionally substituted by one or more R9 g
    Type: Application
    Filed: January 25, 2006
    Publication date: October 26, 2006
    Applicant: Cyclacel Limited
    Inventors: Shudong Wang, Christopher Meades, Darren Gibson, Peter Fischer